Product Overview
CPX-351 | T31088 | TargetMol Chemicals
CAS: 1256639-86-7
Smiles: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O
Formula: C36H42N4O15
Pathway: N/A
Target: N/A
Receptor: N/A
Bioactivity: CPX-351 is a Liposomal-encapsulated combination of daunorubicin and cytarabine for the treatment of newly diagnosed tAML or AML with myelodysplasia-related changes (AML-MRCs).
Molecular Weight: 770, 745
